{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:48:11Z","timestamp":1791557291969,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":587,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hum. Psychopharmacol Clin Exp"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1002\/hup.2387","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T02:06:56Z","timestamp":1390356416000},"page":"183-189","source":"Crossref","is-referenced-by-count":44,"title":["Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study"],"prefix":"10.1002","volume":"29","author":[{"given":"Mengxin","family":"Wang","sequence":"first","affiliation":[{"name":"Shandong University Qilu Hospital; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Clinical and Experimental Sciences, Faculty of Medicine; University of Southampton; Southampton United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jian","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Mi","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqin","family":"Tang","sequence":"additional","affiliation":[{"name":"Shandong Mental Health Center; Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"10.1002\/hup.2387-BIB0001|hup2387-cit-0001","volume-title":"Applied Therapeutics: The Clinical use of Drugs","author":"Alldredge","year":"2009"},{"key":"10.1002\/hup.2387-BIB0002|hup2387-cit-0002","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0015-0282(16)60365-5","article-title":"Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia","volume":"50","author":"Ataya","year":"1988","journal-title":"Fertil Steril"},{"key":"10.1002\/hup.2387-BIB0003|hup2387-cit-0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.physbeh.2009.04.025","article-title":"Estrogen regulation of apoptosis in osteoblasts","volume":"99","author":"Bradford","year":"2010","journal-title":"Physiol Behav"},{"key":"10.1002\/hup.2387-BIB0004|hup2387-cit-0004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.npp.1300412","article-title":"From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions","volume":"29","author":"Emiliano","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/hup.2387-BIB0005|hup2387-cit-0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5435\/00124635-200708000-00002","article-title":"The effects of medications on bone","volume":"15","author":"Goodman","year":"2007","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1002\/hup.2387-BIB0006|hup2387-cit-0006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14740338.2011.560112","article-title":"Risk of osteoporosis and fracture incidence in patients on antipsychotic medication","volume":"10","author":"Graham","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1002\/hup.2387-BIB0007|hup2387-cit-0007","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200721080-00003","article-title":"Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation","volume":"21","author":"Halbreich","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1002\/hup.2387-BIB0008|hup2387-cit-0008","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J Psychiatr Pract"},{"key":"10.1002\/hup.2387-BIB0009|hup2387-cit-0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history of schizophrenia","volume":"190","author":"Howard","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1002\/hup.2387-BIB0010|hup2387-cit-0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1185\/030079903125002865","article-title":"Hyperprolactinaemia and antipsychotic therapy in schizophrenia","volume":"20","author":"Hummer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/hup.2387-BIB0011|hup2387-cit-0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0269881107087955","article-title":"Understanding osteoporosis","volume":"22","author":"Javaid","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0012|hup2387-cit-0012","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.186.4.489","article-title":"Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts","volume":"186","author":"Kameda","year":"1997","journal-title":"J Exp Med"},{"key":"10.1002\/hup.2387-BIB0013|hup2387-cit-0013","first-page":"135","article-title":"Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia","volume":"25","author":"Kaneda","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1002\/hup.2387-BIB0014|hup2387-cit-0014","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1002\/hup.2387-BIB0015|hup2387-cit-0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","article-title":"Reliability and validity of the positive and negative syndrome scale for schizophrenics","volume":"23","author":"Kay","year":"1988","journal-title":"Psychiatry Res"},{"key":"10.1002\/hup.2387-BIB0016|hup2387-cit-0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2005.02.011","article-title":"Bone mineral density measurement in female inpatients with schizophrenia","volume":"77","author":"Kishimoto","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2387-BIB0017|hup2387-cit-0017","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4161\/cc.7.10.5892","article-title":"Unraveling estrogen action in osteoporosis","volume":"7","author":"Krum","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1002\/hup.2387-BIB0018|hup2387-cit-0018","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4306\/pi.2010.7.4.278","article-title":"Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investig"},{"key":"10.1002\/hup.2387-BIB0019|hup2387-cit-0019","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/hup.2387-BIB0020|hup2387-cit-0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol Rev"},{"key":"10.1002\/hup.2387-BIB0021|hup2387-cit-0021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1002\/hup.2387-BIB0022|hup2387-cit-0022","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/hup.2387-BIB0023|hup2387-cit-0023","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.euroneuro.2008.02.004","article-title":"Prolactin awareness: an essential consideration for physical health in schizophrenia","volume":"18","author":"Montejo","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/hup.2387-BIB0024|hup2387-cit-0024","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/hup.2387-BIB0025|hup2387-cit-0025","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/PSY.0b013e3181f7abd3","article-title":"Skeletal status in psychotic disorders: a population-based study","volume":"72","author":"Partti","year":"2010","journal-title":"Psychosom Med"},{"key":"10.1002\/hup.2387-BIB0026|hup2387-cit-0026","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","article-title":"Prolactin and antipsychotic medications: mechanism of action","volume":"35","author":"Petty","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2387-BIB0027|hup2387-cit-0027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0028|hup2387-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-10-1","article-title":"Bone mass in schizophrenia and normal populations across different decades of life","volume":"10","author":"Renn","year":"2009","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1002\/hup.2387-BIB0029|hup2387-cit-0029","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2474-11-35","article-title":"Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients","volume":"11","author":"Renn","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1002\/hup.2387-BIB0030|hup2387-cit-0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hup.984","article-title":"Ultrasound bone mass in schizophrenic patients on antipsychotic therapy","volume":"24","author":"Rey-S\u00e1nchez","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0031|hup2387-cit-0031","first-page":"71","article-title":"Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy","volume":"23","author":"Riecher-R\u00f6ssler","year":"2009","journal-title":"Neuropsychiatr"},{"key":"10.1002\/hup.2387-BIB0032|hup2387-cit-0032","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0033|hup2387-cit-0033","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hup.1250","article-title":"No association between bone mass and prolactin levels among patients with schizophrenia","volume":"26","author":"Sugawara","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0034|hup2387-cit-0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Van Os","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/hup.2387-BIB0035|hup2387-cit-0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130100711","article-title":"Dropout rates in randomized antipsychotic drug trials","volume":"155","author":"Wahlbeck","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/hup.2387-BIB0036|hup2387-cit-0036","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0269881107086516","article-title":"Clinical questions and uncertainty-prolactin measurement in patients with schizophrenia and bipolar disorder","volume":"22","author":"Walters","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1002\/hup.2387-BIB0037|hup2387-cit-0037","unstructured":"World Health Organization 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis"},{"key":"10.1002\/hup.2387-BIB0038|hup2387-cit-0038","unstructured":"World Health Organization 2004 World Health Organization scientific group on the assessment of osteoporosis at the primary health care level"},{"key":"10.1002\/hup.2387-BIB0039|hup2387-cit-0039","unstructured":"World Health Organization 2011 Schizophrenia http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hup.2387\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T14:40:08Z","timestamp":1625150408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2387"}},"subtitle":["BMD AND PROLACTIN LEVELS IN SCHIZOPHRENIA"],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/hup.2387","relation":{},"ISSN":["0885-6222"],"issn-type":[{"value":"0885-6222","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}